MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Search

Celldex Therapeutics Inc

Fechado

SetorSaúde

31 -0.9

Visão Geral

Variação de preço das ações

24h

Atual

Mín

28.21

Máximo

31.31

Indicadores-chave

By Trading Economics

Rendimento

-14M

-81M

Vendas

75K

75K

EPS

-1.22

Margem de lucro

-108,422.667

Funcionários

198

EBITDA

-7.8M

-81M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+72.46% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

346M

2B

Abertura anterior

31.9

Fecho anterior

31

Sentimento de Notícias

By Acuity

100%

0%

334 / 349 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Celldex Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

1 de abr. de 2026, 22:56 UTC

Notícias Principais

Australian PM Set To Announce Interest-Free Loans For Businesses, Farmers

1 de abr. de 2026, 20:50 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Extends Deadline on Tender Offer to Acquire Arcellx

1 de abr. de 2026, 23:55 UTC

Conversa de Mercado

Gold Rises on Hopes for Early End to U.S.-Iran Conflict -- Market Talk

1 de abr. de 2026, 23:43 UTC

Conversa de Mercado

Nikkei May Rise on Continued Hopes for U.S. Ending Iran War -- Market Talk

1 de abr. de 2026, 23:23 UTC

Notícias Principais

South Korea Consumer Inflation Accelerates on Mideast Energy Shock -- Update

1 de abr. de 2026, 23:07 UTC

Ganhos

Shake Shack Leans on Loyalty Program and Tech to Drive Growth -- Barrons.com

1 de abr. de 2026, 23:02 UTC

Notícias Principais

South Korea Consumer Inflation Accelerates on Mideast Energy Shock

1 de abr. de 2026, 23:00 UTC

Notícias Principais

S Korea Mar CPI +0.3% on Month; +0.6% Forecast

1 de abr. de 2026, 23:00 UTC

Notícias Principais

S Korea Mar Core CPI +2.2% on Year, +0.1% on Month

1 de abr. de 2026, 23:00 UTC

Notícias Principais

S Korea Mar CPI +2.2% on Year; +2.4% Forecast

1 de abr. de 2026, 22:39 UTC

Ganhos

Nike Can't Fix Its China Problem and That's Tanking Its Stock -- Update

1 de abr. de 2026, 22:08 UTC

Conversa de Mercado

KKR BDC Joins Others in Capping Withdrawals at 5% -- Market Talk

1 de abr. de 2026, 22:00 UTC

Notícias Principais

Mideast War Rekindles Asia Inflation Risk, Says DBS Chief Economist -- Interview

1 de abr. de 2026, 22:00 UTC

Notícias Principais

DBS Chief Economist: Rate Hikes Seem Likely in Japan, Singapore, Australia

1 de abr. de 2026, 22:00 UTC

Notícias Principais

DBS Chief Economist: BOK Could Also Take Proactive Approach Like RBA

1 de abr. de 2026, 22:00 UTC

Notícias Principais

DBS Chief Economist: India Vulnerable to War Imapct on Both Trade, Energy

1 de abr. de 2026, 22:00 UTC

Notícias Principais

DBS Chief Economist: China, Malaysia Looks Relatively Well-Insulated From War Fallout

1 de abr. de 2026, 22:00 UTC

Notícias Principais

DBS Chief Economist: Mideast Crisis Won't Hurt Asia Growth Much, Inflation a Bigger Issue

1 de abr. de 2026, 22:00 UTC

Notícias Principais

Inflationary Impact of Mideast Conflict Seems Inevitable, DBS Group Chief Economist Says

1 de abr. de 2026, 21:56 UTC

Aquisições, Fusões, Aquisições de Empresas

BHP Completes $4.3 Billion Silver Streaming Agreement With Wheaton Precious Metals

1 de abr. de 2026, 21:31 UTC

Notícias Principais

End to Iran War Could Trigger Relief Rally in These 2 Assets -- Barrons.com

1 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

1 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

1 de abr. de 2026, 20:38 UTC

Ganhos

Why Nike Stock Is in 'Penalty Box' After Earnings Beat -- Barrons.com

1 de abr. de 2026, 20:31 UTC

Aquisições, Fusões, Aquisições de Empresas

Arsenal Capital Partners Completes Sale of ATP Adhesive Systems to Henkel

1 de abr. de 2026, 20:16 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead: Tender Offer Extended to Expire at 5 p.m. EDT on April 24 >GILD

1 de abr. de 2026, 20:16 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead: Offer Remains at a Purchase Price of $115.00 per Shr >GILD

1 de abr. de 2026, 20:13 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Extends Tender Offer To Acquire Arcellx >GILD

1 de abr. de 2026, 20:07 UTC

Conversa de Mercado

Mexican Manufacturing Indexes Pick Up in March -- Market Talk

1 de abr. de 2026, 20:07 UTC

Aquisições, Fusões, Aquisições de Empresas

Why 2026 Is Biotech's Comeback Year -- Barrons.com

Comparação entre Pares

Variação de preço

Celldex Therapeutics Inc Previsão

Preço-alvo

By TipRanks

72.46% parte superior

Previsão para 12 meses

Média 53.91 USD  72.46%

Máximo 90 USD

Mínimo 24 USD

Com base em 12 analistas de Wall Street que oferecem metas de preço de 12 meses para Celldex Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

12 ratings

10

Comprar

1

Manter

1

Vender

Pontuação Técnica

By Trading Central

18.91 / 20.63Suporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
help-icon Live chat